🚀 VC round data is live in beta, check it out!
Hualan Biological Vaccine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hualan Biological Vaccine and similar public comparables like InventisBio, Intellia Therapeutics, Galecto, Pacific Shuanglin and more.
Hualan Biological Vaccine Overview
About Hualan Biological Vaccine
Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.
Founded
2005
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$2B
Hualan Biological Vaccine Financials
Hualan Biological Vaccine reported last fiscal year revenue of $162M and EBITDA of $141M.
In the same fiscal year, Hualan Biological Vaccine generated $132M in gross profit, $141M in EBITDA, and $30M in net income.
Revenue (LTM)
Hualan Biological Vaccine P&L
In the most recent fiscal year, Hualan Biological Vaccine reported revenue of $162M and EBITDA of $141M.
Hualan Biological Vaccine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $162M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $132M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 81% | XXX | XXX | XXX |
| EBITDA | — | XXX | $141M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 87% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 18% | XXX | XXX | XXX |
| Net Profit | — | XXX | $30M | XXX | XXX | XXX |
| Net Margin | — | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hualan Biological Vaccine Stock Performance
Hualan Biological Vaccine has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Hualan Biological Vaccine's stock price is $3.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.9% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHualan Biological Vaccine Valuation Multiples
Hualan Biological Vaccine trades at 9.4x EV/Revenue multiple, and 10.8x EV/EBITDA.
EV / Revenue (LTM)
Hualan Biological Vaccine Financial Valuation Multiples
As of March 18, 2026, Hualan Biological Vaccine has market cap of $2B and EV of $2B.
Equity research analysts estimate Hualan Biological Vaccine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hualan Biological Vaccine has a P/E ratio of 61.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 51.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.6x | XXX | XXX | XXX |
| P/E | — | XXX | 61.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 25.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hualan Biological Vaccine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hualan Biological Vaccine Margins & Growth Rates
Hualan Biological Vaccine's revenue in the last fiscal year declined by (53%).
Hualan Biological Vaccine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (53%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 87% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (69%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 44% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hualan Biological Vaccine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| InventisBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Intellia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Galecto | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Shuanglin | XXX | XXX | XXX | XXX | XXX | XXX |
| Relay Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hualan Biological Vaccine M&A Activity
Hualan Biological Vaccine acquired XXX companies to date.
Last acquisition by Hualan Biological Vaccine was on XXXXXXXX, XXXXX. Hualan Biological Vaccine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hualan Biological Vaccine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHualan Biological Vaccine Investment Activity
Hualan Biological Vaccine invested in XXX companies to date.
Hualan Biological Vaccine made its latest investment on XXXXXXXX, XXXXX. Hualan Biological Vaccine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hualan Biological Vaccine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hualan Biological Vaccine
| When was Hualan Biological Vaccine founded? | Hualan Biological Vaccine was founded in 2005. |
| Where is Hualan Biological Vaccine headquartered? | Hualan Biological Vaccine is headquartered in China. |
| Is Hualan Biological Vaccine publicly listed? | Yes, Hualan Biological Vaccine is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Hualan Biological Vaccine? | Hualan Biological Vaccine trades under 301207 ticker. |
| When did Hualan Biological Vaccine go public? | Hualan Biological Vaccine went public in 2022. |
| Who are competitors of Hualan Biological Vaccine? | Hualan Biological Vaccine main competitors are InventisBio, Intellia Therapeutics, Galecto, Pacific Shuanglin. |
| What is the current market cap of Hualan Biological Vaccine? | Hualan Biological Vaccine's current market cap is $2B. |
| What is the current revenue of Hualan Biological Vaccine? | Hualan Biological Vaccine's last fiscal year revenue is $162M. |
| What is the current EV/Revenue multiple of Hualan Biological Vaccine? | Current revenue multiple of Hualan Biological Vaccine is 9.4x. |
| Is Hualan Biological Vaccine profitable? | No, Hualan Biological Vaccine is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.